Open-Angle Glaucoma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 03 02:32 2021
Open-Angle Glaucoma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Open-Angle Glaucoma – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Open-Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Open-Angle Glaucoma Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Open-Angle Glaucoma pipeline landscapes. 

The report comprises Open-Angle Glaucoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Open-Angle Glaucoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Open-Angle Glaucoma pipeline products.     

Open-Angle Glaucoma Overview

Open-angle glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. It is the most common type of glaucoma. Patients can suffer from it for years without knowing as it comes slowly and painlessly. Open-angle glaucoma usually happens to people over 50. There will be higher pressure in the eyes than the normal eyes, damaging optic nerves over the time. As the nerve breaks down, one gets blind spots.

The risk increases with age and people over 50 years are at most risk, followed by one having family history, and other conditions like diabetes, thin cornea, high blood pressure, and near-sightedness.

Some of the key takeaways from the Open-Angle Glaucoma Pipeline Report:

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Nova Eye Medical, New World Medical, Aurolab, Sight Sciences, Glaukos Corporation, Avedro Inc MicroSurgical Technology (MST), Santen Pharmaceutical, etc., are developing therapies for the treatment of Open-Angle Glaucoma.

Get an overview of pipeline landscape @ Open-Angle Glaucoma Clinical Trials Analysis 

Open-Angle Glaucoma Key Players:

  1. Nova Eye Medical

  2. New World Medical

  3. Aurolab, Sight Sciences

  4. Glaukos Corporation

  5. Avedro, Inc.

  6. MicroSurgical Technology (MST)

  7. Santen Pharmaceutical

Scope of Open-Angle Glaucoma Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Nova Eye Medical, New World Medical, Aurolab, Sight Sciences, Glaukos Corporation, Avedro Inc MicroSurgical Technology (MST), Santen Pharmaceutical, and others.

Table of Contents

1

Open-Angle Glaucoma Report Introduction

2

Open-Angle Glaucoma Executive Summary

3

Open-Angle Glaucoma Overview

4

Open-Angle Glaucoma- Analytical Perspective In-depth Commercial Assessment

5

Open-Angle Glaucoma Pipeline Therapeutics

6

Open-Angle Glaucoma Late Stage Products (Phase II/III)

7

Open-Angle Glaucoma Mild Stage Products (Phase II)

8

Open-Angle Glaucoma Early Stage Products (Phase I)

9

Open-Angle Glaucoma Preclinical Stage Products

10

Open-Angle Glaucoma Therapeutics Assessment

11

Open-Angle Glaucoma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Open-Angle Glaucoma Key Companies

14

Open-Angle Glaucoma Key Products

15

Open-Angle Glaucoma Unmet Needs

16 

Open-Angle Glaucoma Market Drivers and Barriers

17

Open-Angle Glaucoma Future Perspectives and Conclusion

18

Open-Angle Glaucoma Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Open-Angle Glaucoma Drugs Pipeline Report 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/